Barclays raised the firm’s price target on Illumina (ILMN) to $95 from $90 and keeps an Underweight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina launches new business BioInsight
- Illumina to partner with multiple global pharmaceutical companies
- Illumina price target lowered to $124 from $126 at RBC Capital
- Cathie Wood Buys Deere Stock (DE) on Post-Earnings Dip, Builds Stakes in Exact Sciences and Robinhood Stocks
- Icahn exits Illumina, Dana; boosts stakes in CVR Energy